机构:[1]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, People’s Republic of China.深圳市中医院深圳医学信息中心[2]Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA.[3]Department of Chronic Disease Epidemiology, Yale School of Public Health, School of Medicine, Yale University, New Haven, CT 06520‑8034, USA
Liver cancer is the fatal cause of cancer deaths worldwide due to its aggressiveness and lack of effective therapies. Tiliroside (C30H26O13) is an active compound extracted from herb plant Tribulus terrestris L., which has been used as alternative therapy in clinic practice. However, its therapeutic use against liver cancer has not been previously reported. Here, we showed that Tiliroside exerted significantly higher anti-proliferation effect on liver cancer cell lines Hep3B and SNU-449 than on liver normal cell THLE-3 cells or NC group, respectively, by using MTS assay. Results from colony formation, immigration and invasion assays support the anticancer efficacy of Tiliroside and its low-toxic property while treating liver normal cell THLE-3. 3D spheroid formation and CD133 expression level also displays its anti-stemness effect. It has been showed that Tiliroside may function as Carbonic anhydrases XII (CAXII) inhibitor and affects apoptotic E2F1/E2F3/Caspase-3 axis by using CAXII esterase activity assay, Human carbonic anhydrase 12 (CA-12) ELISA Kit, quantitative reverse transcription PCR (RT-qPCR) as well as CaspACE Assay System, respectively. In summary, we demonstrate for the first time that Tiliroside suppresses liver cancer development possibly by acting as a novel CAXII inhibitor, which warrant further investigation on its therapeutic implications.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|3 区综合性期刊
小类|3 区综合性期刊
最新[2025]版:
大类|3 区综合性期刊
小类|3 区综合性期刊
第一作者:
第一作者机构:[1]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, People’s Republic of China.[2]Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA.
通讯作者:
通讯机构:[1]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, People’s Republic of China.[2]Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA.
推荐引用方式(GB/T 7714):
Han Rui,Yang Hongxing,Lu Lingeng,et al.Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis.[J].Scientific reports.2021,11(1):8626.doi:10.1038/s41598-021-88133-7.
APA:
Han Rui,Yang Hongxing,Lu Lingeng&Lin Lizhu.(2021).Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis..Scientific reports,11,(1)
MLA:
Han Rui,et al."Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis.".Scientific reports 11..1(2021):8626